Contrasting Alpha Cognition (ACOG) and Its Competitors

Alpha Cognition (NASDAQ:ACOG) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Alpha Cognition to related businesses based on the strength of its dividends, institutional ownership, risk, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Alpha Cognition and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Earnings & Valuation

This table compares Alpha Cognition and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-2.16
Alpha Cognition Competitors	$574.62 million	-$70.96 million	-0.15

Alpha Cognition’s competitors have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Alpha Cognition and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1924	5381	13923	296	2.58

Alpha Cognition currently has a consensus price target of $20.00, indicating a potential upside of 261.66%. As a group, “Biological products, except diagnostic” companies have a potential upside of 103.08%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than its competitors.

Risk & Volatility

Alpha Cognition has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s competitors have a beta of -3.86, meaning that their average stock price is 486% less volatile than the S&P 500.

Insider & Institutional Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alpha Cognition beats its competitors on 8 of the 13 factors compared.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.